Rottendorf Pharmaceuticals Signs Multiple New Deals

Rottendorf Pharmaceuticals, the US-based subsidiary of German company Rottendorf Pharma, signed in the last quarter three formulation development projects and two commercial transfer projects with multiple top 5 pharmaceutical and biopharmaceutical companies.

"The new projects signed in the last quarter reflect the industry's positive response to our business model and our commitment to Total Process Ownership (TPO)," said Rottendorf Pharmaceuticals CEO Gordon Haines. "TPO relies on open communication and exchange of ideas with our pharma partners and draws on 85 years of formulation development and manufacturing experience to recommend process optimizations to ultimately produce a better end product."

"We are owned by a charitable foundation, which allows us to focus more on long-term success of our business and the goals of our customers, rather than needing to satisfy shareholders on a quarter-by-quarter basis," Haines added.

Recently Rottendorf won five separate 2015 CMO Leadership Awards presented by Life Science Connect. The awards are based on survey results of more than 65,000 questionnaires sent to a broad range of both pharma and biotech companies.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Free Virtual Event

Sustainability in Bioprocessing
Bioprocess Forum

Sustainability in Bioprocessing

Join us to explore hot topics in sustainable bioprocessing like the industrial potential of enzymatic synthesis, innovative biocatalysis techniques, and the use of digital twins in bioprocessing.